10-K - NextCure, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

NextCure, Inc. reported a net loss of $55.8 million for fiscal year 2025, consistent with a net loss of $55.7 million in 2024. The company generated no revenue and incurred total operating expenses of $57.6 million, primarily driven by research and development costs of $44.9 million, which increased due to $18.5 million in license fees and milestone payments for the SIM0505 program. General and administrative expenses decreased to $12.7 million. The company's cash position, including marketable securities, was $41.8 million as of December 31, 2025. Management states this liquidity is insufficient to fund operations for one year, raising substantial doubt about the company's ability to continue as a going concern. The strategic focus remains on advancing clinical-stage ADC candidates SIM0505 and LNCB74.

Key Takeaways

1Net loss of $55.8M in FY 2025, similar to $55.7M loss in prior year.

2Research and development expenses were $44.9M, including $18.5M for SIM0505 license.

3Cash, cash equivalents, and marketable securities totaled $41.8M as of Dec 31, 2025.

4Company has 40 full-time employees as of December 31, 2025.

5Accumulated deficit reached $436.0 million at fiscal year-end 2025.

Key Financial Metrics

EPS

-$20

-$20 prior year

Net Income

-$55.8M